Vascular disrupting agents: a delicate balance between efficacy and side effects

被引:35
作者
Hollebecque, Antoine [1 ]
Massard, Christophe [1 ]
Soria, Jean-Charles [1 ]
机构
[1] Inst Gustave Roussy, Dept Med, Serv Innovat Therapeut Precoces, F-94805 Villejuif, France
关键词
angiogenesis; cardiovascular toxicity; flavonoids; tubulin-binding agents; vascular disrupting agent; PHASE-I TRIAL; COMBRETASTATIN A-4 PHOSPHATE; 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID DMXAA; ADVANCED SOLID TUMORS; TARGETING AGENT; A4; PHOSPHATE; CLINICAL-EVALUATION; TUBULIN POLYMERIZATION; ANTIVASCULAR AGENT; TZT-1027;
D O I
10.1097/CCO.0b013e32835249de
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review Targeting the tumor vasculature is an attractive approach for cancer therapy. Vascular disrupting agents (VDAs) are compounds that directly target tumor blood vessels and create central tumor necrosis. The current review aims to summarize the clinical development (i.e. safety and efficacy) of this class of compounds. Recent findings VDAs have demonstrated signs of clinical activity in different tumor types [e.g. anaplastic thyroid carcinoma (ATC), nonsmall cell lung carcinoma (NSCLC), ovarian cancer, sarcoma]. However, the lack of predictive biomarkers to identify patients with a high probability of response to VDAs, places this class of compounds at a high risk of failure. This has recently been exemplified by several negative phase II/III trials in NSCLC, ATC, and castration-refractory metastatic prostate cancer. Summary VDAs represent a unique class of anticancer compounds. Their clinical development is hampered by cardiovascular, neurological toxicities as single agent and by hematological toxicity in combination with chemotherapy. Molecular predictors of their efficacy are crucial for further development. As single agent, only few objective responses have been observed in a variety of solid tumors. However, VDAs have failed to demonstrate a survival advantage in several phase II/III trials especially in combination with chemotherapy.
引用
收藏
页码:305 / 315
页数:11
相关论文
共 74 条
[1]  
[Anonymous], 2011, ASCO M
[2]  
Anthony SP, 2007, J CLIN ONCOL, V25
[3]   Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [J].
Beerepoot, LV ;
Radema, SA ;
Witteveen, EO ;
Thomas, T ;
Wheeler, C ;
Kempin, S ;
Voest, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) :1491-1498
[4]   Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation [J].
Bertelsen, Lotte B. ;
Shen, Yuan Yuan ;
Nielsen, Thomas ;
Stodkilde-Jorgensen, Hans ;
Lloyd, G. Kenneth ;
Siemann, Dietmar W. ;
Horsman, Michael R. .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2011, 87 (11) :1126-1134
[5]   Phase I trial of combretastatin A-4 phosphate with carboplatin [J].
Bilenker, JH ;
Flaherty, KT ;
Rosen, M ;
Davis, L ;
Gallagher, M ;
Stevenson, JP ;
Sun, WJ ;
Vaughn, D ;
Giantonio, B ;
Zimmer, R ;
Schnall, M ;
O'Dwyer, PJ .
CLINICAL CANCER RESEARCH, 2005, 11 (04) :1527-1533
[6]  
Blakey DC, 2002, CLIN CANCER RES, V8, P1974
[7]  
BOUCHER Y, 1990, CANCER RES, V50, P4478
[8]   Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J].
Carmeliet, Peter ;
Jain, Rakesh K. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :417-427
[9]  
Chebil M, 2009, J CLIN ONCOL, V27
[10]   The Safety and Tolerability of Intravenous ASA404 When Administered in Combination with Docetaxel (60 or 75 mg/m2) in Japanese Patients with Advanced or Recurrent Solid Tumors [J].
Daga, Haruko ;
Hida, Toyoaki ;
Ishikawa, Shizu ;
Shimizu, Junichi ;
Tokunaga, Shinya ;
Horio, Yoshitsugu ;
Kobayashi, Ken ;
Takeda, Koji .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (09) :1067-1073